India is increasingly becoming a preferred destination for clinical trials. By 2025, the Indian market is expected to reach US$ 3.15billion with a CAGR of 8.7 percent. The increasing demand creates a need for market expertise and research authenticity to optimise the productivity with increased foreign investments and growing partnerships with local players.
Being initiated as an academic training institute for Drug Inspection and Pharmacist training in 2004, RAHE group has its foundations on qualitative expertise as a contract research organisation. Mukesh Kumar, Director and CEO of Rahe Life Science says, “The way we are maintaining our quality standards are actually followed as per our Company’s SOP, ICH-GCP guidelines, CDSCO & USFDA standards.”
Integrating Healthcare to Ease Patient Suffering
Mukesh continues, “Drug maker and sponsor companies are under pressure to replace the revenue loss caused by generics, increasing patentexpiry, number of partnerships to identify biologics, and growing R&D costs, which has made drug development more expensive and complex. Market for clinical trials is mainly driven
by increasing demand for innovative solutions in healthcare industry, alliance between the pharma-biotechmedical device companies with CROs and advancements in technology.”
RAHE Life sciences are providing services in Allopathic, Ayurveda, Nutraceuticals, Homeopathy and Medical devices. It prioritises on delivering its solutions tailor made with client’s preference. The company has a large footprint in the Indian market and has dedicated its efforts to consistency and strategic international expansion. It aims to provide end to end services delivered with quality hallmarks to the clients within their specifications.
We are working hard and maintaining good relations with our clients by fulfilling their work requirements with quality assurance
Analyse, Scrutinise and Consult
Rahe Life Sciences works tirelessly to improve the clinical research measures with continued upgradation and security checks. Technological knowhow is a key part of its quality standards and operational protocol. Mukesh adds, “The domain we are responsible for is clinical research and hence we do ensure that our clients take care of the subjects who are getting involved in to the study and help to predict the actual action of the drug.
Therefore, the way leading to completion of all by maintaining all the standards of ICH- GCP guidelines and Indian GCP guidelines along with the set rules of regulatory authorities, CDSCO and USFDA. We anyhow imprint our presence and prove to be the best. We have also time to time participated in various governmental programs, exhibitions, FDP, etc., to learn more and earn more.”
The major focus of Rahe Life sciences currently is to derive ways of curbing the pandemic covid-19. Mukesh concludes, “Our main goal is becoming India’s leading CRO. We are working hard and maintaining good relations with our clients by fulfilling their work requirements with quality assurance. Also managing to enter at international level and make our own name and fame there. We want to be there for all of our national and international clients and make them feel proud of us by our way and quality of work.”